GILEAD SCIENCES, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
GILEAD SCIENCES, INC. (GILD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $65.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2026-02-24
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-09-30 was $389.00M.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-06-30 was $0.00.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2022-03-31 was $2.70B.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for the quarter ending 2020-09-30 was $511.00M.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $65.00M, a 91.98% decline from fiscal 2024.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $810.00M, a 820.45% increase from fiscal 2023.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $88.00M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|---|---|---|
| 2025-12-31 | $65.00M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $810.00M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $88.00M 10-K · filed 2026-02-24 | |||
| 2022-09-30 | $389.00M 10-Q · filed 2022-11-02 | $389.00M derived: sum of 2 quarters · filed 2023-08-04 | $389.00M 10-Q · filed 2022-11-02 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $2.70B 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $2.70B 10-Q · filed 2023-05-03 | |||
| 2020-09-30 | $511.00M 10-Q · filed 2020-11-04 | $5.01B derived: sum of 2 quarters · filed 2021-11-03 | $4.50B 10-Q · filed 2020-11-04 | |
| 2020-06-30 | $4.50B 10-Q · filed 2021-11-03 | $4.50B 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |